Market Place
Sourcing Support
Alkermes plc Reports Third Quarter 2024 Financial Results
24 Oct 2024 //
PR NEWSWIRE
Alkermes to Host Investor Event to Review Orexin Portfolio
25 Sep 2024 //
PR NEWSWIRE
Alkermes To Present ALKS 2680 Data At Sleep Europe 2024
23 Sep 2024 //
PR NEWSWIRE
Alkermes To Attend Morgan Stanley Healthcare Conference
28 Aug 2024 //
PR NEWSWIRE
Alkermes Initiates Phase 2 Study Of ALKS 2680 For Narcolepsy
22 Aug 2024 //
PR NEWSWIRE
Alkermes impresses in full-throttle narcolepsy race with Takeda
04 Jun 2024 //
FIERCE BIOTECH
Alkermes` ALKS 2680 Improved Wakefulness In Narcolepsy Type 1 At SLEEP
03 Jun 2024 //
PR NEWSWIRE
Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024
28 May 2024 //
PR NEWSWIRE
Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
02 May 2024 //
PR NEWSWIRE
Alkermes Completes $91M Sale of Athlone Facility to Novo Nordisk
02 May 2024 //
CONTRACT PHARMA
Alkermes plc Reports First Quarter 2024 Financial Results
01 May 2024 //
PR NEWSWIRE
Alkermes Initiates Vibrance-1 Phase 2 Narcolepsy Study
24 Apr 2024 //
PR NEWSWIRE
Alkermes to Report Q1 Financial Results on May 1
17 Apr 2024 //
PR NEWSWIRE
Alkermes ALKS 2680 Improves Wakefulness In Narcolepsy, Hypersomnia
09 Apr 2024 //
PR NEWSWIRE
Alkermes Presents Analyses From Long-Term Safety Study of LYBALV at SIRS
08 Apr 2024 //
PR NEWSWIRE
Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors
07 Mar 2024 //
PRESS RELEASE
Alkermes Reports Financial Results for the Fourth Quarter and Year Ended
15 Feb 2024 //
PR NEWSWIRE
Alkermes reports strong trajectory for Lybalvi, shares up 10%
15 Feb 2024 //
FIERCE PHARMA
Alkermes to Report Fourth Quarter & Year-End Financial Results on Feb. 15, 2024
08 Feb 2024 //
PRESS RELEASE
JPM24: Alkermes ready to roll as pure-play neuroscience company
10 Jan 2024 //
FIERCE PHARMA
Alkermes Announces Topline Results From Study of LYBALVI
03 Jan 2024 //
PR NEWSWIRE
Corporate Governance at Alkermes
20 Dec 2023 //
ACCESSWIRE
Alkermes` Commitment to Integrity and Compliance
18 Dec 2023 //
ACCESSWIRE
Novo puts down $92.5M for Alkermes` Ireland plant, staffers
15 Dec 2023 //
FIERCE PHARMA
Alkermes` Culture of Employee Engagement and Wellness
14 Dec 2023 //
ACCESSWIRE
Patient Advocacy and Community Engagement at Alkermes
11 Dec 2023 //
ACCESSWIRE
Alkermes to Participate in Two Upcoming Investor Conferences
21 Nov 2023 //
PRESS RELEASE
Alkermes Celebrates #Movember for Men’s Health Awareness Month
20 Nov 2023 //
ACCESSWIRE
Alkermes` Waste Optimization Highlights
16 Nov 2023 //
ACCESSWIRE
Mural wants to paint new picture in IL-2 after Alkermes spinout
15 Nov 2023 //
FIERCE BIOTECH
Alkermes Completes Separation of Oncology Business
15 Nov 2023 //
PR NEWSWIRE
Environmental Health and Safety at Alkermes
08 Nov 2023 //
ACCESSWIRE
Alkermes to Participate in the Jefferies London Healthcare Conference
07 Nov 2023 //
PRESS RELEASE
Operating and Growing Responsibly at Alkermes
31 Oct 2023 //
ACCESSWIRE
Alkermes Announces Effectiveness of Mural Form 10 Registration Statement
31 Oct 2023 //
PR NEWSWIRE
Alkermes plc Reports Third Quarter 2023 Financial Results
25 Oct 2023 //
PR NEWSWIRE
Alkermes CEO Reflects on Living Company Purpose
23 Oct 2023 //
ACCESSWIRE
Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680
23 Oct 2023 //
PR NEWSWIRE
Alkermes to Report Third Quarter Financial Results on October 25, 2023
18 Oct 2023 //
PR NEWSWIRE
Alkermes Proudly Announces Release of 2023 Corporate Responsibility Report
11 Oct 2023 //
ACCESSWIRE
Alkermes to Present First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680
10 Oct 2023 //
PR NEWSWIRE
Alkermes Commemorates World Suicide Prevention Day
18 Sep 2023 //
ACCESSWIRE
Alkermes Presents Clinical and Real-World Data at 36th Annual Psych Congress
11 Sep 2023 //
PR NEWSWIRE
Alkermes Announces Launch of Annual Alkermes Pathways Research Awards Program
07 Sep 2023 //
PR NEWSWIRE
Alkermes to Participate in Two Upcoming Investor Conferences
05 Sep 2023 //
PR NEWSWIRE
Alkermes Announces Settlement With Teva Related to VIVITROL® Patent Litigation
30 Aug 2023 //
PR NEWSWIRE
Alkermes` $194M payment from Janssen gets approval from court
21 Aug 2023 //
ENDPTS
Alkermes hikes up financials by $425M after Invega license fight win against J&J
31 Jul 2023 //
ENDPTS
Alkermes posts Q2 sales gain after winning J&J arbitration case
26 Jul 2023 //
FIERCE PHARMA
Alkermes plc Reports Second Quarter 2023 Financial Results
26 Jul 2023 //
PR NEWSWIRE
Sarissa`s board push drew little support in Alkermes shareholder vote
06 Jul 2023 //
ENDPTS
Alkermes shareholders reject 3 board nominees from Sarissa
30 Jun 2023 //
FIERCE PHARMA
Alkermes Shareholders Re-Elect All Seven Company Director Nominees at Meeting
29 Jun 2023 //
YAHOO FINANCE
Alkermes shareholders re-elect directors, rebuffing effort by hedge fund Sarissa
29 Jun 2023 //
STAT NEWS
Sarissa and Alex Denner lose fight for board seats at Alkermes
29 Jun 2023 //
ENDPTS
Recently-Appointed Directors of Alkermes Issue Open Letter to Shareholders
26 Jun 2023 //
PR NEWSWIRE
Alkermes board replacements largely fail to win support from shareholder firms
21 Jun 2023 //
ENDPTS
Independent Proxy Advisory Firm ISS Recommends Alkermes Shareholders
20 Jun 2023 //
PR NEWSWIRE
Alkermes Participates in ALPFA’s Latina Summit
14 Jun 2023 //
ACCESSWIRE
Sarissa goes after Alkermes, seeking three board seats at the Irish drugmaker
13 Jun 2023 //
ENDPTS
